P&G’s exit from the switch picture adds “salt to a wound left by” Somaxon’s unsuccessful prescription Silenor launch in 2010, Jeffries analysts note. Somaxon recently laid off 75% of its sales staff and drastically cut marketing to minimize its cash burn rate, which far outpaced initial sales.
Cash-strapped Somaxon Pharmaceuticals Inc. scrambles to find a partner to switch a version of the sleep aid Silenor to OTC after long-time co-promoter Procter & Gamble Co. walked away from exclusive marketing rights.
P&G’s decision March 29 not to work with Somaxon to develop and market an OTC version of the doxepin drug...
Create an account to read this article
Already a subscriber?
The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.
Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”
Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.
Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.
Complaints about TPAs offer an explanation of why self-funded employers continue to use the big three PBMs despite concerns about those relationships. Proposed solutions include banning retaliatory fees and data withholding.
While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.
